Ionis Pharmaceuticals, Inc.

United States of America


 
Total IP 859
Total IP Rank # 1,536
IP Activity Score 3.5/5.0    554
IP Activity Rank # 1,306
Stock Symbol
ISIN US4622221004
Market Cap. 6,000M  (USD)
Industry Biotechnology
Sector Healthcare
Dominant Nice Class Pharmaceutical, veterinary and s...

Patents

Trademarks

502 49
67 7
220 6
8
 
Last Patent 2025 - Compounds and methods for reduci...
First Patent 1992 - Oligonucleotides containing 2′-o...
Last Trademark 2025 - KNOW YOUR TGS
First Trademark 2015 - IONIS PHARMACEUTICALS

Industry (Nice Classification)

Latest Inventions, Goods, Services

2025 G/S Financial and insurance consultation services, namely, patient advisory, support and consultancy ...
G/S Providing on-line non-downloadable software for use in organizing, and conducting individual supp...
G/S Mobile healthcare services; Health care services, namely, providing support and services for dise...
G/S Organizing and conducting support groups in the field of healthcare; Providing emotional counseli...
G/S Pharmaceuticals for treatment of genetic diseases and disorders; pharmaceuticals for treatment of...
G/S Pharmaceutical preparations and substances for the treatment of edema, namely hereditary angioede...
G/S Medical services; medical information services; providing a website featuring medical and healthc...
G/S Pharmaceutical preparations and substances in the field of neurodevelopmental and neurodegenerati...
G/S Education and training services, namely, seminars, providing non-downloadable webinars, and works...
G/S Providing healthcare information, medical information, and pharmaceutical information online, by ...
2024 Invention Modulation of gene expression. The present embodiments provide methods of modulating gene express...
Invention Compounds and methods for modulating acute activation. Provided herein are pharmaceutical composi...
Invention Methods for modulating ube3a-ats. Provided are methods of administering ION582 for reducing the a...
Invention Compounds and methods for modulating smn2. Disclosed herein are compounds, compositions and meth...
Invention Modulators of apol1 expression. The present embodiments provide methods, compounds, and composit...
Invention Methods and compositions for reducing angiotensinogen. Provided herein are methods of reducing th...
Invention Compounds and methods for modulating cln3 expression. Provided are compounds, methods, and pharma...
Invention Modulators of malat1 expression. The present embodiments provide methods, compounds, and composi...
G/S Medical services; medical information services; providing medical and healthcare information for...
Invention Cell-targeting complexes and uses thereof. Provided are complexes and methods for targeting cells...
Invention Compounds and methods for inhibiting lpa. Provided are oligomeric duplexes, oligomeric compounds ...
Invention Compounds and methods for inhibiting lpa. Provided are oligomeric agents, methods, and pharmaceut...
Invention Compounds and methods for reducing apociii expression. Provided are oligomeric agents, methods, a...
Invention Editing systems and components and uses thereof. Provided are guided nucleic acid binding agents,...
Invention Compositions and methods for modulating pkk expression. Disclosed herein are antisense compounds...
Invention Compounds and methods for reducing atn1 expression. Provided are oligomeric agents, methods, and ...
Invention Compounds and methods for reducing tubb4a expression. Provided are compounds, methods, and pharma...
Invention Compositions and methods to treat liver, kidney and cell proliferative diseases and disorders. Di...
Invention Cd29 targeted oligonucleotides and uses thereof. Embodiments provided herein are directed to olig...
Invention Modulation of alpha synuclein expression. Disclosed herein are antisense compounds and methods f...
Invention Compounds and methods for the modulation of proteins. In certain embodiments, the present disclo...
Invention Sugar modified oligonucleotides and uses thereof. The present disclosure provides RNAi agents com...
G/S Pharmaceuticals for treatment of genetic diseases and disorders; pharmaceuticals for treatment o...
Invention Compounds and methods for modulation of dystrophia myotonica-protein kinase (dmpk) expression. P...
Invention Compounds and methods for reducing pln expression. Provided are oligomeric compounds, methods, a...
Invention Compounds and methods for reducing pln expression. Provided are oligomeric compounds, methods, an...
Invention Methods and compositions for inhibiting pmp22 expression. The present embodiments provide method...
Invention Allele-selective compounds and methods for modulating huntingtin expression. Provided herein are...
Invention Compounds and methods for reducing app expression. Provided are compounds, methods, and pharmace...
Invention Compounds and methods for reducing atxn2 expression. Provided are compounds, methods, and pharma...
Invention Compositions and methods for modulating apolipoprotein c-iii expression. Provided herein are oli...
2023 Invention Selective antisense compounds and uses thereof. The present invention provides oligomeric compou...
G/S Pharmaceutical preparations and substances for the treatment of edema, namely hereditary angioed...
Invention Compounds and methods for reducing lrrk2 expression. Provided are compounds, methods, and pharmac...
Invention Compositions and methods for modulating apolipoprotein (a) expression. Provided herein are oligom...
Invention Compounds and methods for increasing stmn2 expression. Provided are compounds, methods, and phar...
Invention Compositions for modulating ataxin 2 expression. Disclosed herein are antisense compounds and me...
Invention Modulators of enac expression. The present embodiments provide methods, compounds, and compositi...
Invention Modulation of prekallikrein (pkk) expression. Disclosed herein are antisense compounds and metho...
G/S Pharmaceutical research and development in the field of genetic diseases and disorders; providing...
Invention Selective reduction of allelic variants. Disclosed herein are antisense compounds and methods fo...
Invention Compounds and methods for reducing atxn3 expression. Provided are compounds, methods, and pharma...
2022 Invention Compounds and methods for modulating glycogen synthase 1. Provided are compounds, methods, and p...
Invention Compounds and methods for modulating progranulin expression. Provided are oligomeric compounds, ...
Invention Conjugated oligonucleotides and uses thereof. Provided herein are oligomeric compounds comprisin...
Invention Compounds and methods for reducing dmpk expression. Provided are oligomeric compounds, methods, ...
Invention Compounds and methods for modulating scn1a expression. Provided are oligomeric compounds, method...
Invention Compounds and methods for reducing ifnar1 expression. Provided are oligomeric agents, oligomeric...
Invention Linkage modified oligomeric compounds and uses thereof. The present disclosure provides oligomer...
Invention Compounds and methods for modulating huntingtin. Provided are compounds, methods, and pharmaceut...
Invention Compounds and methods for reducing dux4 expression. Provided are compounds, pharmaceutical compo...